Pioneering AI-Powered Biopsy Assessment
Veripath is at the forefront of revolutionizing biopsy procedures across multiple medical disciplines through cutting-edge AI technology.
The Growing Challenge in Biopsy Procedures
Biopsy inadequacy rates have surged from 2% in 2005 to 14% in 2020, with kidney biopsies particularly affected, posing significant challenges to healthcare systems and patient care.
Inadequate biopsies lead to potential misdiagnoses and the need for repeat procedures, increasing patient discomfort and health risks.
The shift to radiologist-performed biopsies and use of smaller needles has contributed to a decrease in biopsy quality and increased healthcare costs.
Our Solution
Veripath has developed a web-based software using deep learning for real-time, quantitative assessment of biopsy adequacy directly from smartphone photographs. Our platform supports multiple tissue types, with kidney biopsies as a primary use case.
- Highlights cortex areas in kidney biopsy images as an example application
- Determines tissue-specific adequacy metrics for various biopsy types
- Utilizes state-of-the-art image segmentation architecture
- Adaptable across multiple tissue types and clinical scenarios
Join Us in Advancing Biopsy Technology
Veripath is committed to pushing the boundaries of AI-assisted biopsy assessment. We invite collaboration with researchers, clinicians, and institutions to further validate and expand our technology.
Contact Our Research Team